Navigation Links
Acesys and Provid Announce Alliance for Medicinal Chemistry Services
Date:9/3/2008

NORTH BRUNSWICK, N.J. and NANJING, China, Sept. 3 /PRNewswire/ -- Acesys Pharmatech and Provid Pharmaceuticals Inc. announce a strategic alliance, combining the drug discovery expertise and project management capabilities of Provid in the US with the medicinal chemistry resources and favorable cost structure of Acesys in China.

The combined services available through the alliance will encompass all aspects of medicinal chemistry for clients in the pharmaceutical and biotech industries.

An experienced team at Provid will be involved in the design of programs, in the creation of novel intellectual property, and in exploratory research. Acesys will provide support for these projects with scaffold construction, hit-to-lead exploration, focused library synthesis, analog synthesis and other aspects of drug discovery.

Each project will operate via an alliance team including scientists and a program leader from Provid, a senior team leader and medicinal chemists from Acesys, and the client's representatives. Blending the US and China efforts will enable clients to benefit from the combined experience, emphasis on high quality, productivity, and sophisticated science, coupled with lower costs.

"We have explored opportunities for alliances with emerging companies in China for some time," said Dr. Gary Olson, Provid CEO, "and have been impressed by the exceptionally well-qualified and experienced drug discovery chemists that lead the Acesys organization. They have many years of successful CRO experience serving international pharmaceutical and biotech companies."

"With Provid's years of experience in medicinal chemistry and project management, Acesys will be able to provide low-cost medicinal chemistry service with uniquely high quality and high productivity," said Charles Ye, CEO and President of Acesys Pharmatech, "Provid has proved its expertise in medicinal chemistry in numerous projects, and has a great track record. The alliance will be a valuable resource to our clients."

About Provid

Provid Pharmaceuticals Inc. is a drug discovery service company that provides expert medicinal chemistry support to the biotech and pharmaceutical industries. These services aid a variety of research organizations ranging from start-ups and virtual development companies to large pharma, as well as government labs and academic groups. Provid applies world-class medicinal chemistry and drug development experience to transform the biological discoveries made by our customers into commercial opportunities.

For more details, see: http://www.providpharma.com.

About Acesys Pharmatech

Acesys Pharmatech is a contract research company that provides services in medicinal chemistry, including custom synthesis (from gram to kilogram), exploratory medicinal chemistry, and full medicinal chemistry project support. Acesys has extensive experience in library design and synthesis, using solution phase and solid-phase technology. In addition to its medicinal chemistry services, Acesys has built other alliances and collaborations that provide comprehensive pharmaceutical research outsourcing, including exploratory DMPK, preliminary toxicology and animal models for preclinical R&D. For details, visit our website: http://www.acesysweb.com.

Contacts:

Gary Olson, Ph.D.

President & CEO

Provid Pharmaceuticals Inc.

671 US Route 1, North Brunswick, NJ 08902

gary.olson@providpharma.com

732-565-1101 x 626

Charles Ye

President & CEO

Acesys Pharmatech, Ltd

5 Xinmofan Road, Technology Building B-2407, Nanjing 210009, China

yye@acesysweb.com

Tel: 908-998-1240


'/>"/>
SOURCE Provid Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Roche Joins Forces With Enon Tabernacle Baptist Church to Provide Free Hepatitis C Testing to the Community
2. CardioDynamics Provides 2007 Shareholder Meeting Update
3. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
4. Center for Molecular Medicine Only Regional Provider of Test Suggested in FDA Alert on Prescribing Codeine to Nursing Mothers
5. Reed Group to Provide MDA Internet Disability Duration Guidelines to U.S. Navy
6. ZymoGenetics Will Hold Conference Call Today at 5:00 p.m. Eastern Time to Provide Update on rThrombin
7. Baxter to Launch GARDian(TM), a Groundbreaking Initiative That Helps Provide Continued Access to GAMMAGARD for Current Patients
8. Niceware International Announces Licensed Vendor Status with ICCBBA, Inc. to Provide ISBT 128-compliant Software
9. NxStage Medical Provides Update on Medisystems Acquisition
10. VaxGen Files 2006 Financial Statements and Provides Cash Update
11. Signalife Provides Corporate Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... 2016 Australian-US drug discovery and development company, Novogen ... of a new Chairman, Mr John O,Connor , and ... James Garner , has also been formally ... Acting CEO, Mr Iain Ross , will resume his ... James Garner , has also been formally appointed to ...
(Date:2/4/2016)... - New FDA action date of July ... action date of July 22, 2016   --> ... 22, 2016   - Lifitegrast has the ... for the treatment of signs and symptoms of dry eye disease ... to be the only product approved in the U.S. in the past decade indicated for ...
(Date:2/4/2016)... ... , ... Shimadzu Scientific Instruments will showcase several new products, ... sessions, and present on the analysis of mycotoxins and medical cannabis at the ... at the Georgia World Congress Center in Atlanta, Georgia. , Attendees should ...
(Date:2/4/2016)... -- Beike Biotechnology, the Shenzhen ... in late 2015 to mark their successful combined efforts ... --> --> The signing, ... Therapy" was hosted by the Shenzhen Cell Bank and ... Beike Biotechnology Co., Ltd. Shenzhen,s ...
Breaking Biology Technology:
(Date:2/2/2016)... , Feb. 2, 2016  Based on its ... & Sullivan recognizes US-based Intelligent Retinal Imaging Systems ... Sullivan Award for New Product Innovation. IRIS, a ... North America , is poised to ... growing diabetic retinopathy market. The IRIS technology presents ...
(Date:1/28/2016)... Jan. 28, 2016 Synaptics (NASDAQ: SYNA ), a ... its second quarter ended December 31, 2015. ... of fiscal 2016 increased 2 percent compared to the comparable quarter ... of fiscal 2016 was $35.0 million, or $0.93 per diluted share. ... income for the first quarter of fiscal 2016 grew 9 percent ...
(Date:1/22/2016)... January 22, 2016 ... addition of the  "Global Behavioral Biometric ... --> http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) has ... Behavioral Biometric Market 2016-2020"  report to ... and Markets ( http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) has announced ...
Breaking Biology News(10 mins):